Qiagen v. Bio-Rad: Six-Patent Cell Capture & Droplet IP Dispute Dismissed With Prejudice
Qiagen Hamburg GmbH and Qiagen LLC brought a declaratory judgment action against Bio-Rad Laboratories in Delaware, asserting six patents spanning cell capture systems and fluid-partitioning-based chemical amplification. The case ran 468 days before closing on a joint stipulation dismissed with prejudice by Chief Judge Connolly.
Qiagen's Declaratory Judgment Bid Against Bio-Rad Ends With Finality
On 6 April 2022, Qiagen Hamburg GmbH and Qiagen LLC filed a declaratory judgment action against Bio-Rad Laboratories in the U.S. District Court for the District of Delaware (Case No. 1:22-cv-00458), before Chief Judge Colm F. Connolly. The complaint involved six patents — US11231355B2, USRE041780E, US11237096B2, US11073468B2, US10782226B1, and US10921237B2 — covering cell capture systems and chemical amplification techniques based on fluid partitioning in immiscible liquids, core technologies in single-cell biology and digital PCR workflows.
The recorded basis of termination is 'Dismissed with Prejudice.' The docket order states that the case was closed pursuant to a Joint Stipulation and Order of Dismissal 'So Ordered' by Chief Judge Connolly. A dismissal with prejudice is a final adjudication on the merits as a matter of law, barring Qiagen from refiling the same declaratory judgment claims against Bio-Rad on these patents. The specific terms underlying the parties' joint stipulation are not disclosed in the available public record.
The case closed on 18 July 2023, approximately 15 months after filing — a relatively compact timeline for a six-patent declaratory judgment action in Delaware. What drove the parties to jointly stipulate to dismissal with prejudice at this stage of proceedings, and whether any commercial arrangement was reached between Qiagen and Bio-Rad, is not apparent from the public record.
See Complete Case & Patent Analysis →Filing to Dismissed with Prejudice in 468 days
468 days from filing to dismissal — roughly 15 months of active litigation in Delaware
US11231355B2 and five further patents — cell capture and droplet partitioning technology
Any company developing or commercialising cell capture hardware, droplet microfluidic systems, or immiscible-liquid-based amplification reagents should treat this six-patent portfolio as a priority FTO target. The asserted patents span both the physical capture layer and the fluidic chemistry layer of single-cell workflows, meaning a single product in this space may face exposure across multiple patents simultaneously. The absence of any invalidity or claim construction ruling from this litigation means there is no court-generated guidance to narrow the claims.
Official order — verbatim text
The case was terminated by a Joint Stipulation and Order of Dismissal entered by Chief Judge Connolly. The recorded basis of termination is 'Dismissed with Prejudice,' making the disposition final and barring re-filing of these declaratory judgment claims. No merits ruling on patent validity or infringement was issued, and the specific terms underlying the parties' joint agreement are not disclosed in the available public record.
Dismissed with prejudice: what the joint stipulation means for both parties
Dismissed with prejudice bars re-filing on these six patents
A dismissal with prejudice operates as a final judgment on the merits. Qiagen cannot refile declaratory judgment claims against Bio-Rad on US11231355B2, USRE041780E, US11237096B2, US11073468B2, US10782226B1, or US10921237B2 in any U.S. federal court. The dismissal was entered by joint stipulation — both parties agreed to the mechanism — and was formally So Ordered by Chief Judge Connolly, giving it full judicial force.
Res judicata appliesQiagen's declaratory judgment path is permanently closed
As the party seeking a declaratory judgment, Qiagen had aimed to resolve uncertainty over its freedom to operate under the six asserted patents. The with-prejudice dismissal forecloses that declaratory route. Whether Qiagen obtained any commercial certainty through a separate arrangement is not disclosed in the available public record.
DJ claims extinguishedBio-Rad retains its patent portfolio without a validity ruling
Bio-Rad faced declaratory judgment claims that could have resulted in invalidity or non-infringement findings across six patents central to its droplet and cell-capture IP estate. The dismissal with prejudice ends that threat from Qiagen in this proceeding. Because no court ruled on patent validity or infringement, Bio-Rad's patents emerge from this litigation without any adverse finding on the merits.
No adverse validity rulingSix patents covering key single-cell and droplet PCR methods remain unchallenged
The six patents span cell capture systems and immiscible-liquid fluid-partitioning amplification — foundational methods in single-cell genomics and digital PCR. Their validity was never adjudicated in this proceeding. Competitors and product teams working in these technology areas should note that these patents remain enforceable and that the litigation record provides no claim construction or invalidity guidance they can rely on.
Patents remain enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Qiagen Hamburg, GmbH | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Qiagen, LLC | Company | Search in Eureka ↗ |
| Defendant | Bio-Rad Laboratories | Company | /Search in Eureka ↗ |
| Plaintiff counsel | David A. Bilson | Attorney | Counsel for Qiagen Hamburg, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | John C. Phillips | Attorney | Counsel for Qiagen Hamburg, GmbHSearch in Eureka ↗ |
| Plaintiff law firm | Phillips, Goldman, McLaughlin & Hall PA | Law Firm | Representing Qiagen Hamburg, GmbHSearch in Eureka ↗ |
| Defendant counsel | Brian E. Farnan | Attorney | Counsel for Bio-Rad LaboratoriesSearch in Eureka ↗ |
| Defendant counsel | Derek C. Walter | Attorney | Counsel for Bio-Rad LaboratoriesSearch in Eureka ↗ |
| Defendant counsel | Edward R. Reines | Attorney | Counsel for Bio-Rad LaboratoriesSearch in Eureka ↗ |
| Defendant counsel | Michael J. Farnan | Attorney | Counsel for Bio-Rad LaboratoriesSearch in Eureka ↗ |
| Defendant law firm | Farnan LLP | Law Firm | Representing Bio-Rad LaboratoriesSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the cell capture and droplet partitioning IP space
Forward-looking patent intelligence derived from the Qiagen–Bio-Rad dispute across cell capture systems and immiscible-liquid amplification technology.
Qiagen's filing activity in single-cell capture and microfluidics
Qiagen's assertion of five utility patents filed in 2020–2021 suggests an active continuation filing strategy in cell capture and droplet microfluidics. Monitoring Qiagen's pending applications in these technology domains can reveal where the company is seeking to extend claim scope — and where white space may exist for design-around opportunities.
Active continuation strategyDroplet partitioning and digital PCR patent filing trends
The immiscible-liquid fluid-partitioning domain underpinning digital PCR has seen accelerating patent filings from multiple players including Bio-Rad, 10x Genomics, and emerging single-cell tool vendors. Mapping the citation network around USRE041780E and US10921237B2 can reveal which newer filings build on — or seek to design around — the foundational chemistry claims in this space.
Competitive filing accelerationBio-Rad's layered cell-capture and droplet IP estate
Bio-Rad's six-patent portfolio spans both capture hardware and fluidic chemistry, suggesting a deliberate strategy to surround the single-cell workflow with overlapping IP. Analysing Bio-Rad's continuation and divisional filings beyond the six asserted patents can reveal the full perimeter of its IP fence — critical intelligence for any competitor planning a cell biology product launch.
Multi-layer IP fenceAdjacent opportunities in cell isolation outside immiscible-liquid partitioning
The concentration of IP in immiscible-liquid droplet partitioning and conventional cell capture hardware suggests potential white space in alternative cell isolation modalities — such as microwell arrays, deterministic lateral displacement, or acoustofluidic sorting — where the forward-citation density of the six asserted patents is lower. These adjacencies may offer lower-risk development paths for new entrants.
Alternative isolation modalitiesSimilar declaratory judgment cases in cell capture and droplet PCR IP
Explore related declaratory judgment disputes involving cell capture systems, droplet microfluidics, and digital PCR patents litigated in U.S. District Courts.
What this case signals for the single-cell and droplet PCR IP landscape
A six-patent declaratory judgment action dismissed with prejudice in 15 months — here is what it means for players in this space.
DJ actions in droplet PCR are a live IP risk management tool
Qiagen's filing of a declaratory judgment action — rather than waiting to be sued — signals that the cell capture and droplet partitioning space is contested enough for market participants to proactively seek patent certainty. Companies with overlapping product lines should assess whether their exposure warrants a similar posture or whether cross-licensing is a more efficient path.
No validity ruling means Bio-Rad's six patents carry full enforcement weight
Because the case ended without any claim construction, invalidity finding, or non-infringement ruling, all six patents — covering cell capture systems and fluid-partitioning amplification — remain enforceable with an unimpaired presumption of validity. Any third party commercialising products in these technology areas faces the same landscape as before this litigation began.
Qiagen v Bio-Rad — key questions answered
Qiagen Hamburg GmbH and Qiagen LLC asserted six patents: US11231355B2, USRE041780E, US11237096B2, US11073468B2, US10782226B1, and US10921237B2. These cover cell capture systems and methods of use, and chemical amplification techniques based on fluid partitioning in immiscible liquids.
The recorded basis of termination is 'Dismissed with Prejudice.' The docket order states the case was closed pursuant to a Joint Stipulation and Order of Dismissal So Ordered by Chief Judge Colm F. Connolly on 18 July 2023. The specific terms underlying the joint stipulation are not disclosed in the available public record.
A dismissal with prejudice operates as a final judgment on the merits as a matter of law. Qiagen cannot refile the same declaratory judgment claims against Bio-Rad on these six patents in any U.S. federal court. The dismissal was entered by joint stipulation, meaning both parties agreed to this mechanism.
No. The case ended before any merits adjudication. No claim construction order, invalidity finding, or non-infringement ruling was issued. All six asserted patents retain their full presumption of validity and enforceability. The litigation record provides no claim-construction guidance that third parties can rely on.
USRE041780E is a reissue patent — an earlier U.S. patent that was corrected or broadened through the USPTO reissue process. Based on the product categories identified in the case record, it relates to chemical amplification based on fluid partitioning in an immiscible liquid, a foundational method underlying droplet digital PCR workflows. The application number on record is US12/118418.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.